Literature DB >> 6765289

The immunopathology of progressive systemic sclerosis (PSS).

D C Haynes, M E Gershwin.   

Abstract

Progressive systemic (sclerosis) is one of the most enigmatic of the rheumatic diseases. It is a connective tissue disorder of unknown etiology characterized by fibrosis in skin and internal organs. Although similar lesions are found with increased prevalence in workers exposed to coal, gold, silica, and polyvinyl chloride, most patients have had no known predisposing factors. Select reports of a familial occurrence of PSS have been observed but a definitive genetic basis is lacking and no clear associations with the major histocompatability complex have been demonstrated. Moreover, although a variety of immunologic abnormalities in patients with PSS have been reported, they are generally diffuse and non-diagnostic. Such abnormalities include defects in cell mediated immunity, increases in sera immunoglobulins, antinuclear antibodies, and cryoglobulins. In contrast to these non-specific findings, there appears to be significant evidence of a relationship between cell mediated immunity to collagen and appearance of scleroderma. For example, peripheral blood lymphocytes in patients with scleroderma undergo lymphocyte transformation when cultured with specific collagen preparations. The pathology of skin and internal organs in PSS generally reflects both collagen deposition and small vessel occlusion. All organ systems may be involved but mortality significantly increases with involvement of heart, kidney, or lung. Unfortunately, at present a reliable experimental model of PSS has not been found although similar immunopathology can be induced in homologous disease of rats and in chronic graft vs host disease of humans.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6765289     DOI: 10.1016/0049-0172(82)90055-5

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

1.  Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma.

Authors:  R Sgonc; M S Gruschwitz; H Dietrich; H Recheis; M E Gershwin; G Wick
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis.

Authors:  P J Maddison; R P Skinner; R S Pereira; C M Black; B M Ansell; M I Jayson; N R Rowell; K I Welsh
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

3.  Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis.

Authors:  A Kahan; A Kahan; C J Menkes; B Amor
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

4.  Animal model of human disease. Avian scleroderma. An inherited fibrotic disease of white Leghorn chickens resembling progressive systemic sclerosis.

Authors:  J van de Water; M E Gershwin
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

5.  Elevated transcription of heat shock protein gene in scleroderma fibroblasts.

Authors:  Y Deguchi; N Shibata; S Kishimoto
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

6.  The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Authors:  Stephen W Mamber; Vit Long; Ryan G Rhodes; Sunthorn Pond-Tor; Lyn R Wheeler; Kellie Fredericks; Brian Vanscoy; Jean-Frederic Sauniere; Remy Steinschneider; Jean-Claude Laurent; John McMichael
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.